Ophthalmic Drugs: World Market 2011-2021

• Publication date: March 2011

Where will the highest revenue growth occur in the ophthalmic drug market? Our new report shows you the eye disorder treatment market's potential from 2011 to 2021. We forecast and explain the commercial opportunities there. Our report gives you revenue predictions for ophthalmic treatments from 2011 to 2021. We aim to save you time and aid your decisions through our research, data and discussions. You can stay ahead by ordering our report...

Where will the highest revenue growth occur in the ophthalmic drug market? Our new report shows you the eye disorder treatment market's potential from 2011 to 2021. We forecast and explain the commercial opportunities there.

Our report gives you revenue predictions for ophthalmic treatments from 2011 to 2021. We aim to save you time and aid your decisions through our research, data and discussions. You can stay ahead by ordering our report now.

You will discover revenue prospects for eye disorder drugs at total world, sub-market, product and national levels. We cover drugs for glaucoma, retinal disorders, dry eye, ocular allergy, inflammation and infection. 

In particular, our report shows you how 22 leading ophthalmic drugs will perform to 2021. We forecast revenues for Lucentis, Visudyne, Xalatan, Travatan, Lumigan, Restasis, Patanol, Vigamox and others. 

You will discover ophthalmic revenue prospects for Pfizer, Novartis, Allergan, Merck & Co., Roche and other companies from 2011 onwards.

Our review of ophthalmic R&D includes drug delivery technologies and neuroprotective agents. We discuss the many emerging technologies in ophthalmics. You will discover what products can transform the eye drug market in the future. 

Our new study discusses how companies will overcome challenges - commercial, regulatory, therapeutic and technological - in the world ophthalmic drug market.

We show how companies can seize ophthalmic market opportunities in developed and developing countries. You will see how some organisations can succeed against competition, economic uncertainties and pricing concerns. 

We help you to assess the industry's strengths, weaknesses, trends and opportunities from 2011. You will see where ophthalmics is heading and what companies will do in future. 

Our report gives you data, analyses and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Industry and market analysis to help your work - so you won't be left behind

Our report gives you revenue forecasts, growth rates, market shares, SWOT analysis, an R&D review and external opinions from our survey. We include 94 tables and charts and three research interviews (shown in the accompanying lists).

We can help you now, making it easier for you to stay ahead in this industry and market.

Ophthalmic Drugs: World Market 2011-2021 shows you revenue trends, opportunities and challenges

Our report gives you the following advantages:
• You will receive hard data for the ophthalmic drug industry and market - especially our revenue forecasts to 2021
• You will discover sales trends for the overall market and its main components from 2009 to 2021 - seeing where revenue growth will occur
• You will see revenue prospects for leading products from 2011 to 2021, with discussions of market potential and competition
• You will find revenue prospects for leading national markets from 2011 to 2021 (US, Japan, UK, Germany, France, Spain, Italy, China, India and Brazil)
• You will learn how the ophthalmic treatments industry will change from 2011 to 2021
• You will assess leading companies providing ophthalmic drug treatments, discovering their activities, outlooks and revenue prospects
You will investigate competition and opportunities influencing the world ophthalmic drug market from 2011 onwards
• You will see what will stimulate and restrain the industry and market from 2011
• You will review ophthalmic technologies, assessing pharma R&D potential
• You will investigate commercial requirements - with therapeutic needs and sales opportunities discussed
• You will analyse opportunities for established companies and those seeking to enter the ophthalmics market
• You will view opinions from our survey, including full interview transcripts.

That mix of quantitative and qualitative market analysis sets our report apart. The emphasis is on future revenue trends - distinctive predictions from our work. Our independent analysis helps you to stay ahead in commercial knowledge for eye disorders.

Order our report now to gain industry and market information you need 

Our report can benefit everybody interested in ophthalmic market analysis, product development, production, marketing and sales. We give predictions and answers you need. Don't miss out - please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

NB: All visiongain reports are password locked so please let us know what licence is most suitable for your business needs

Global Ophthalmic Devices Industry

Table of Contents

1. Executive Summary
1.1 Aims, Scope and Format of the Report
1.2 Research and Analysis Methods

2. Ophthalmic Disorders and Treatments
2.1 The Ophthalmic Drug Market
2.2 Ophthalmic Disorders
2.3 The Human Eye and the Vision Process
2.4 Glaucoma
2.4.1 Primary Open Angle Glaucoma: The Most Common Type of Glaucoma
2.4.2 Closed Angle Glaucoma
2.4.3 Secondary Glaucoma
2.4.4 Congenital Glaucoma
2.4.5 Normal Tension Glaucoma
2.4.6 Ocular Hypertension
2.4.7 Glaucoma Risk Factors
2.4.8 Diagnosis of Glaucoma
2.4.9 Prevalence of Glaucoma
2.4.10 Treatment of Glaucoma
2.4.11 Prostaglandins are the First-Line Treatment of Choice
2.4.12 Second-Line Glaucoma Treatments
2.4.13 Combination Treatments
2.4.14 Laser Treatment
2.4.15 Surgery (Trabeculectomy)
2.5 Age-Related Macular Degeneration (AMD)
2.5.1 Dry AMD
2.5.2 Wet AMD 
2.5.3 AMD Risk Factors
2.5.4 Diagnosis of AMD
2.5.5 Prevalence of AMD
2.5.6 Treatment of AMD
2.6 Diabetic Retinopathy
2.6.1 Diagnosis of Diabetic Retinopathy
2.6.2 Prevalence of Diabetic Retinopathy
2.6.3 Laser and Surgical Treatments are the Main Treatments for Diabetic Retinopathy
2.6.4 Pharmaceutical Treatments
2.7 Ophthalmic Allergies
2.7.1 Allergic Conjunctivitis is the Most-Common Eye Allergy
2.7.2 Ophthalmic Allergy Treatments
2.8 Ophthalmic Inflammatory Disorders
2.8.1 Uveitis is the Most Common Ocular Inflammatory Disease
2.8.2 Ophthalmic Inflammatory Drugs
2.9 Ophthalmic Infections
2.9.1 Types of Eye Infection
2.9.2 Treatment of Eye Infections
2.10 Dry Eye Syndrome
2.10.1 Causes and Prevalence of Dry Eye Syndrome
2.10.2 The Mainstay of Dry Eye Treatment is Artificial Tears
2.10.3 Prescription-Only Drugs for Dry Eye
2.10.4 Tear Augmenters (Punctal Plugs)

3. The World Ophthalmic Pharmaceutical Market, 2011-2021
3.1 The Ophthalmic Pharmaceutical Market in 2009
3.1.1 The Anti-Glaucoma Segment had the Largest Market Share in 2009
3.1.2 Top Twenty Ophthalmic Pharmaceutical Brands, 2009
3.1.3 Three Manufacturers Account for Almost Half the Market
3.2 World Ophthalmic Pharmaceutical Market Forecasts, 2009-2021
3.2.1 Generic Competition in the Ophthalmic Pharmaceutical Market from 2009-2015
3.2.2 What are the Prospects for the Ophthalmic Pharmaceutical Market from 2016-2021?
3.3 Ophthalmic Pharmaceutical Therapeutic Category Market Forecasts, 2009-2021
3.3.1 Retinal Disorders Will Power Growth from 2009-2015
3.3.2 Retinal Disorder Revenue Growth Will Continue from 2016-2018
3.3.3 High Growth and Return to Market-Leading Position for Anti-Glaucoma Drugs from 2018 to 2021?

4. The Anti-Glaucoma Market, 2011-2021
4.1 The Anti-Glaucoma Treatment Market in 2009
4.1.1 Prostaglandin Analogues Led the Anti-Glaucoma Market in 2009
4.1.2 Xalatan
4.1.3 Travatan
4.1.4 Lumigan
4.1.5 Cosopt
4.1.6 Alphagan
4.1.7 Azopt
4.1.8 Xalacom
4.1.9 Trusopt
4.1.10 Combigan
4.1.11 Extravan/Duotrav
4.2 Anti-Glaucoma Market Forecasts, 2009-2021
4.2.1 Generic Competition Will Affect the Anti-Glaucoma Market from 2009-2015
4.2.2 Novel Anti-Glaucoma Drugs Will Drive Growth from 2016-2021
4.2.3 Xalatan Sales Forecast, 2009-2021
4.2.4 Travatan Sales Forecast, 2009-2021
4.2.5 Lumigan Sales Forecast, 2009-2021
4.2.6 Cosopt Sales Forecast, 2009-2021
4.2.7 Alphagan Sales Forecast, 2009-2021
4.2.8 Azopt Sales Forecast, 2009-2021
4.2.9 Xalacom Sales Forecast, 2009-2021
4.2.10 Trusopt Sales Forecast, 2009-2021
4.2.11 Combigan Sales Forecast, 2009-2021
4.2.12 Extravan/DuoTrav Sales Forecast, 2009-2021

5. The Ophthalmic Anti-Allergy/Inflammatory/Infective Market, 2011-2021
5.1 The Ophthalmic Anti-Allergy/Inflammatory/Infective Treatment Market in 2009
5.1.1 Patanol
5.1.2 Vigamox/Vegamox
5.1.3 TobraDex
5.1.4 Pataday
5.1.5 Acular
5.1.6 Cravit
5.1.7 Zymar
5.2 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Forecasts, 2009-2021
5.2.1 Innovation in the Anti-Allergy/Inflammatory/Infective R&D Pipeline
5.2.2 Patanol Sales Forecast, 2009-2021
5.2.3 Vigamox Sales Forecast, 2009-2021
5.2.4 TobraDex Sales Forecast, 2009-2021
5.2.5 Pataday Sales Forecast, 2009-2021
5.2.6 Acular Sales Forecast, 2009-2021
5.2.7 Cravit Sales Forecast, 2009-2021
5.2.8 Zymar Sales Forecast, 2009-2021

6. The Retinal Disorder Market, 2011-2021
6.1 The Retinal Disorder Treatment Market
6.1.1 Wet AMD has the Largest Market Share of the Retinal Disorder Market
6.1.2 Lucentis Took Control of the Retinal Disorder Market in 2009
6.1.3 Visudyne was the Second Highest Selling Retinal Disorder Drug in 2009
6.1.4 Lucentis has Sidelined Macugen but Faces Potent Threat from Avastin
6.2 Retinal Disorder Market Forecasts, 2009-2021
6.2.1 Lucentis Will Drive the Retinal Disorder Market from 2009-2016
6.2.2 Novel Drugs and New Disease Treatments will Drive Growth from 2016-2021
6.2.3 Lucentis Sales Forecast, 2009-2021
6.2.4 Visudyne Sales Forecast, 2009-2021

7. The Dry Eye Market, 2011-2021
7.1 The Dry Eye Treatment Market in 2009
7.1.1 Restasis is the Only Prescription Drug for Dry Eye in the US
7.1.2 Hyalein: Marketed in Japan and China
7.1.3 Allergan's Celluvisc is the Third-Best-Selling Dry Eye Brand
7.1.4 The OTC Market for Artificial Tears is Fragmented and Competitive
7.2 Dry Eye Market Forecasts, 2009-2021
7.2.1 Increased Sales of Dry Eye Prescription Drugs from 2009-2013?
7.2.2 Growth in the Dry Eye Market Will Decline after 2013
7.2.3 Restasis Sales Forecast, 2009-2021
7.2.4 Hyalein Sales Forecast, 2009-2021
7.2.5 Celluvisc Sales Forecast, 2009-2021

8. Issues Affecting the Market for Ophthalmic Drugs, 2011-2021
8.1 SWOT Analysis of the Ophthalmic Drugs Market
8.2 Strengths of the Ophthalmic Pharmaceutical Market
8.2.1 Development of New Drug Delivery Methods and Formulations
8.2.2 Intraocular Injections
8.2.3 Sustained-Release Ocular Implants
8.2.4 Gene Therapy and RNA Interference Technology
8.2.5 New Ophthalmic Therapeutic Applications for Drugs 
8.2.6 Development of Neuroprotective Anti-Glaucoma Medications
8.3 Weaknesses of the Ophthalmic Pharmaceutical Market
8.3.1 The Ophthalmic Pharmaceutical Market Will Face Generic Competition 
8.3.2 Avastin is Cannibalising Lucentis Revenues
8.4 Opportunities for the Ophthalmic Pharmaceutical Market
8.4.1 Aging of the World Population
8.4.2 Increasing Prevalence of Diabetes
8.4.3 Increasing Prevalence of Eye Disorders
8.4.4 Retinal Disorders Will Have the Most-Marked Increases in Prevalence
8.4.5 Increasing Prevalence of Glaucoma, Dry Eye and Other Ophthalmic Disorders
8.4.6 Generous Reimbursement for Ophthalmic Pharmaceuticals?
8.5 Threats Facing the Ophthalmic Pharmaceutical Market
8.5.1 Poor Patient Compliance
8.5.2 The Rate of Diagnosis for Eye Disorders is Low

9. National Markets for Ophthalmic Pharmaceuticals, 2011-2021 
9.1 Leading Ophthalmic Pharmaceutical Country Markets, 2009
9.2 Leading Developed-Country Ophthalmic Pharmaceutical Markets, 2009-2021
9.2.1 The US Ophthalmic Pharmaceutical Market, 2009-2021
9.2.2 The Japanese Ophthalmic Pharmaceutical Market, 2009-2021
9.2.3 Leading European Ophthalmic Pharmaceutical Markets, 2009-2021
9.3 Emerging-Economy Ophthalmic Pharmaceutical Markets, 2009-2021
9.3.1 Ophthalmic Pharmaceuticals are Making the Leap to Developing Countries
9.3.2 The Chinese Ophthalmic Pharmaceutical Market, 2009-2021
9.3.3 The Indian Ophthalmic Pharmaceutical Market, 2009-2021

10. The Ophthalmic Pharmaceutical R&D Pipeline
10.1 The Ophthalmic Pharmaceutical Pipeline: Richest in Anti-Glaucoma and Retinal Disorder Drugs
10.2 The Anti-Glaucoma Pipeline
10.2.1 Neuroprotection Will Be the Most Important Anti-Glaucoma Pipeline Development
10.2.2 Taflotan/DE-085 (Santen/Asahi)
10.2.3 Azarga (Alcon)
10.2.4 PF-4217329 (Pfizer)
10.2.5 Anecortave (Alcon)
10.2.6 DNB-001 (Danube)
10.2.7 BVT.28949 (Biovitrum)
10.2.8 OT-730 (Othera/QLT)
10.2.9 AL-37807 (Alcon/Novartis)
10.2.10 QLT's Punctal Plug Delivery Technology
10.2.11 PF-03187207 (NicOx/Pfizer)
10.3 The Ophthalmic Anti-Allergy Pipeline
10.3.1 Bepreve (ISTA/Senju)
10.3.2 FOV1101/Prednisporin (Fovea/CombinatoRx)
10.3.3 DE-103 (Santen)
10.4 The Ophthalmic Anti-Inflammatory Pipeline
10.4.1 T-Pred (ISTA)
10.4.2 AzaSite Plus/ASV-502 (InSite Vision)
10.4.3 Durezol (Senju/Sirion Therapeutics)
10.4.4 Luveniq (Lux Biosciences)
10.4.5 Simulect (Cerimon)
10.4.6 EGP-437 (EyeGate Pharma)
10.5 The Ophthalmic Anti-Infective Pipeline
10.5.1 TobraDex ST (Alcon)
10.5.2 ISV-403/Besifloxacin (Bausch & Lomb)
10.5.3 Moxifloxacin/Dexamethasone (Alcon)
10.5.4 Aganocide (Alcon/NovaBay)
10.6 The Retinal Disease Pipeline
10.6.1 Retinal Diseases Have the Richest Pipeline
10.6.2 Arxxant (Eli Lilly/Alcon/Takeda)
10.6.3 Vitrase/Vitragen (ISTA)
10.6.4 Aflibercept/VEGF Trap-Eye (Regeneron/Bayer)
10.6.5 Bevasiranib/Cand5 (OPKO)
10.6.6 Atacand/TCV-116 (AstraZeneca/Takeda)
10.6.7 Medidur (pSivida/Alimera Sciences/Pfizer)
10.6.8 NT-501 (Neurotech)
10.6.9 Microplasmin (ThromboGenics)
10.6.10 Sustained-Release Brimonidine (Allergan)
10.6.11 RTP801i-14/PF-4523655/PF-655 (Quark/Silence/Pfizer)
10.6.12 AGN-745/SIRNA-027 (Allergan/Merck & Co.)
10.6.13 ATG-3 (CoMentis)
10.6.14 OT-551 (Othera)
10.6.15 Fenretinide (Sirion Therapeutics)
10.6.16 RPE65 Gene Therapy (Targeted Genetics)
10.7 The Dry Eye Pipeline
10.7.1 Prolacria (Inspire/Allergan/Santen)
10.7.2 Cyclosporine Ophthalmic Solution (Sirion Therapeutics)
10.7.3 Rebamipide (Otsuka/Acucela)
10.7.4 DE-101/Rivoglitazone (Santen)
10.7.5 Ecabet Sodium (ISTA)
10.7.6 Remura (ISTA)
10.7.7 SAR 1118 (SARcode)
10.8 The Pipeline for Other Ophthalmic Indications Includes Eyelash Growth Stimulators

11. Expert Views from Our Survey
11.1 Professor Leonard Bielory, MD, Director, STARx Allergy and Asthma Centre, LLC and Professor of Medicine, Pediatrics, Ophthalmology and Visual Sciences, Rutgers University, Springfield, NJ, USA
11.1.1 Anterior Inflammatory Disease: Under-diagnosed and Under-treated?
11.1.2 On Current Developments in Ocular Inflammation and Therapeutic Agents
11.1.3 On Future Treatments for Ophthalmic Inflammatory Disorders
11.1.4 R&D and Pipeline Developments
11.1.5 On Therapeutic Areas Offering Growth Opportunities
11.2 Dr Al Reaves, PhD, Senior Vice President of Clinical Development, Othera Pharmaceuticals Inc., Conshohocken, PA, USA
11.2.1 Which Areas of the Ophthalmic Pharmaceutical Market will Experience the Most Growth?
11.2.2 Othera's Geographic Atrophy Drug OT-551
11.2.3 How Will Glaucoma be Treated in 2021?
11.2.4 Othera's Neuroprotective Anti-Glaucoma Drug OT-440
11.2.5 Othera's New Generation Beta Blocker OT-730
11.2.6 New Drugs for Ophthalmic Conditions Currently with No Treatments
11.3 Dr Victor Chong, MD, FRCS, FRCOphth, Consultant Ophthalmic Surgeon and Clinical Senior Lecturer in Ophthalmology, University of Oxford, Oxford Eye Hospital, Oxford, UK
11.3.1 Key Unmet Needs
11.3.2 Research and Development
11.3.3 Problems with the Current Use of Ophthalmic Treatments
11.3.4 Challenges in the Development of Ophthalmic Drugs
11.3.5 Complexities Involved in Developing New Ophthalmic Drugs
11.3.6 Growth Opportunities in the Ophthalmic Drug Market
11.3.7 Challenges Facing the Ophthalmic Pharmaceutical Industry
11.3.8 Main Regions Offering Growth Potential Worldwide
11.3.9 Needs of Glaucoma Patients
11.3.10 Future Treatments for Glaucoma
11.3.11 Pipeline Developments from a Physician's Perspective
11.3.12 Prospects for Replacing Current Treatments
11.3.13 Novel Treatments for Ophthalmic Disorders

12. Conclusions
12.1 The Ophthalmic Pharmaceutical Market
12.2 Visiongain's Ophthalmic Pharmaceutical Market Forecast, 2009-2021
12.3 Who Will Succeed in the Ophthalmic Pharmaceutical Market?
12.4 Where Will the Ophthalmic Pharmaceutical Market Grow Fastest?

List of Tables

Table 2.1 Glaucoma Drug Types, 2011
Table 2.2 AMD Drug Types, 2011
Table 2.3 Ophthalmic Allergy Drug Types, 2011
Table 2.4 Ophthalmic Inflammatory Disorder Drug Types, 2011
Table 2.5 Ophthalmic Anti-Infective Drug Types, 2011
Table 3.1 Ophthalmic Pharmaceutical Therapeutic Category Market Shares, 2010
Table 3.2 Top Twenty Ophthalmic Pharmaceutical Brands, 2009
Table 3.3 Top Ten Ophthalmic Pharmaceutical Manufacturers, 2009
Table 3.4 World Ophthalmic Pharmaceutical Market Forecast, 2009-2015
Table 3.5 World Ophthalmic Pharmaceutical Market Forecast, 2016-2021
Table 3.6 Ophthalmic Pharmaceutical Therapeutic Category Forecasts, 2009-2015
Table 3.7 Ophthalmic Pharmaceutical Therapeutic Category Forecasts, 2016-2021
Table 4.1 Leading Anti-Glaucoma Treatment Brands, 2009
Table 4.2 World Anti-Glaucoma Market Forecast, 2009-2015
Table 4.3 World Anti-Glaucoma Market Forecast, 2016-2021
Table 4.4 Leading Anti-Glaucoma Brands: Sales Forecasts, 2009-2015
Table 4.5 Leading Anti-Glaucoma Brands: Sales Forecasts, 2016-2021
Table 5.1 Therapeutic Category Market Shares in the Ophthalmic Anti-Allergy/ Inflammatory/Infective Market, 2009
Table 5.2 Leading Anti-Allergy/Inflammatory/Infective Treatment Brands, 2009
Table 5.3 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Forecast, 2009-2015
Table 5.4 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Forecast, 2016-2021
Table 5.5 Leading Anti-Allergy/Inflammatory/Infective Brands: Sales Forecasts, 2009-2015
Table 5.6 Leading Anti-Allergy/Inflammatory/Infective Brands: Sales Forecasts, 2016-2021
Table 6.1 Therapeutic Category Market Shares in the Retinal Disorders Market, 2009
Table 6.2 Leading Retinal Disorder Treatment Brands, 2009
Table 6.3 World Retinal Disorders Market Forecast, 2009-2015
Table 6.4 World Retinal Disorders Market Forecast, 2016-2021
Table 6.5 Leading Retinal Disorder Brands: Sales Forecasts, 2009-2015
Table 6.6 Leading Retinal Disorder Brands: Sales Forecasts, 2016-2021
Table 7.1 Leading Dry Eye Treatment Brands, 2009
Table 7.2 World Dry Eye Market Forecast, 2009-2015
Table 7.3 World Dry Eye Market Forecast, 2016-2021
Table 7.4 Leading Dry Eye Brands: Sales Forecasts, 2009-2015
Table 7.5 Leading Dry Eye Brands: Sales Forecasts, 2016-2021
Table 8.1 SWOT Analysis: Strengths and Weaknesses of the World Ophthalmic Drugs Market, 2011-2021
Table 8.2 SWOT Analysis: Opportunities and Threats in the World Ophthalmic Drugs Market, 2011-2021
Table 8.3 Expected Patent Expiries for Leading Ophthalmic Pharmaceuticals, 2010-2014
Table 8.4 Ophthalmic Disorder Prevalence Forecasts to 2030
Table 9.1 Leading Ophthalmic Pharmaceutical Country Markets, 2009
Table 9.2 Leading Ophthalmic Pharmaceutical Country Market Forecasts, 2009-2015
Table 9.3 Leading Ophthalmic Pharmaceutical Country Market Forecasts, 2016-2021
Table 10.1 Key Drugs in the Anti-Glaucoma Pipeline, 2011
Table 10.2 Key Drugs in the Ophthalmic Anti-Allergy Pipeline, 2011
Table 10.3 Key Drugs in the Ophthalmic Anti-Inflammatory Pipeline, 2011
Table 10.4 Key Drugs in the Ophthalmic Anti-Infective Pipeline, 2011 (Part 1)
Table 10.5 Key Drugs in the Ophthalmic Anti-Infective Pipeline, 2011 (Part 2)
Table 10.6 Key Drugs in the Dry Eye Pipeline, 2011
Table 10.7 Key R&D Pipeline Drugs for Other Ophthalmic Indications, 2011

List of Figures

Figure 3.1 Ophthalmic Pharmaceutical Therapeutic Category Market Shares, 2009
Figure 3.2 Top Ten Ophthalmic Pharmaceutical Manufacturers, 2010
Figure 3.3 World Ophthalmic Pharmaceutical Market Forecast, 2009-2021
Figure 3.4 Ophthalmic Pharmaceutical Therapeutic Category Market Shares and Forecasts, 2009-2021
Figure 3.5 Ophthalmic Pharmaceutical Therapeutic Category Forecasts, 2009-2021
Figure 4.1 Leading Anti-Glaucoma Brands, 2010
Figure 4.2 World Anti-Glaucoma Market Forecast, 2009-2021
Figure 4.3 Leading Anti-Glaucoma Brands, 2015
Figure 4.4 Xalatan Sales Forecast, 2009-2021
Figure 4.5 Travatan Sales Forecast, 2009-2021
Figure 4.6 Lumigan Sales Forecast, 2009-2021
Figure 4.7 Cosopt Sales Forecast, 2009-2021
Figure 4.8 Alphagan Sales Forecast, 2009-2021
Figure 4.9 Azopt Sales Forecast, 2009-2021
Figure 4.10 Xalacom Sales Forecast, 2009-2021
Figure 4.11 Trusopt Sales Forecast, 2009-2021
Figure 4.12 Combigan Sales Forecast, 2009-2021
Figure 4.13 Extravan/DuoTrav Sales Forecast, 2009-2021
Figure 5.1 Therapeutic Category Market Shares in the Ophthalmic Anti-Allergy/Inflammatory/Infective Market, 2009
Figure 5.2 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Forecast, 2009-2021
Figure 5.3 Patanol Sales Forecast, 2009-2021
Figure 5.4 Vigamox Sales Forecast, 2009-2021
Figure 5.5 TobraDex Sales Forecast, 2009-2021
Figure 5.6 Pataday Sales Forecast, 2009-2021
Figure 5.7 Acular Sales Forecast, 2009-2021
Figure 5.8 Cravit Sales Forecast, 2009-2021
Figure 5.9 Zymar Sales Forecast, 2009-2021
Figure 6.1 Therapeutic Category Market Shares in the Retinal Disorders Market, 2009
Figure 6.2 Leading Retinal Disorder Brands, 2010
Figure 6.3 World Retinal Disorder Market Forecast, 2009-2021
Figure 6.4 Lucentis Sales Forecast, 2009-2021
Figure 6.5 Visudyne Sales Forecast, 2009-2021
Figure 7.1 World Dry Eye Market Forecast, 2009-2021
Figure 7.2 Restasis Sales Forecast, 2009-2021
Figure 7.3 Hyalein Sales Forecast, 2009-2021
Figure 7.4 Celluvisc Sales Forecast, 2009-2021
Figure 8.1 Global Population Aged Over 65, 2010-2025
Figure 8.2 Population Aged 65 Years or Over in Major Ophthalmic Pharmaceutical Country Markets, 2009 and 2025
Figure 8.3 Global Prevalence of Diabetes and Diabetic Retinopathy, 2007 and 2030
Figure 9.1 Leading Ophthalmic Pharmaceutical Country Markets, 2010
Figure 9.2 Leading Ophthalmic Pharmaceutical Country Markets, 2015
Figure 9.3 Leading Ophthalmic Pharmaceutical Country Markets, 2018
Figure 9.4 Leading Ophthalmic Pharmaceutical Country Markets, 2021
Figure 9.5 US and Japanese Ophthalmic Pharmaceutical Market Forecasts, 2009-2021
Figure 9.6 European, Brazilian, Indian and Chinese Ophthalmic Pharmaceutical Market Forecasts, 2009-2021
Figure 12.1 World Ophthalmic Pharmaceutical Market Forecast, 2009-2021

Companies Listed

Acucela 
Alcon (Novartis)
Alimera Sciences
Allergan
American Academy of Ophthalmology (AAO) [US]
American Society of Retina Specialists (ASRS) [US]
Apotex
Asahi Glass 
AstraZeneca 
Bausch & Lomb 
Bayer 
Biovitrum
Bristol-Myers Squibb
Can-Fite BioPharma
Cerimon Pharmaceuticals 
Chugai Pharmaceutical Corp.
CombinatoRx 
CoMentis
Daiichi Sankyo
Danube Pharmaceuticals
Eli Lilly and Company
Esteve
European Medicines Agency (EMEA/EMA)
EyeGate Pharmaceuticals
Food and Drug Administration (FDA) [US]
Fovea Pharmaceuticals
Galderma International SA (Nestlé and L'Oréal)
Genentech 
GlaxoSmithKline
Gruenenthal
InSite Vision 
Inspire Pharmaceuticals
ISTA Pharmaceuticals
Kowa Company
KYORIN Pharmaceutical Corp.
Kyowa Hakko Kirin Corp.
Laboratorios Sophia 
LEO Pharma 
Lux Biosciences
Johnson & Johnson
Meda Pharmaceuticals
Merck & Co.
Ministry of Health, Labour and Welfare [Japan]
Moorfields Eye Hospital [UK]
Mylan 
National Eye Institute (NEI) [US]
National Health Service (NHS) [UK]
National Institute for Health and Clinical Excellence (NICE) [UK]
National Institutes of Health (NIH) [US]
Neurotech
NicOx
NovaBay Pharmaceuticals
Novartis 
OPKO Health
OSI Pharmaceuticals
Othera Pharmaceuticals
Otsuka Pharmaceutical Corp.
Oxford Eye Hospital [UK]
Pfizer
pSivida Corp.
QLT
Quark Pharmaceuticals
Ranbaxy Laboratories
Regeneron Pharmaceuticals
ReVision Therapeutics
Roche
Rutgers University, Springfield, New Jersey [US]
Santen Pharmaceutical Corp.
Sanwa Kagaku Kenkyusho Corp.
SARcode Corporation
Senju Pharmaceuticals 
Sirion Therapeutics
Sirna Therapeutics
Sunesis Pharmaceuticals
Takeda Pharmaceuticals Corp.
Targeted Genetics Corp.
ThromboGenics
University College of London (UCL), Institute of Ophthalmology [UK]
University of Aston, Birmingham [UK] 
University of Oxford [UK]